glp-1 receptor agonists blindness risk The cardiovascular effects of beyond obesity and type 2 diabetes: An anti-atherosclerotic action Glucagon-Like Peptide-1 Receptor Agonists and
Description
ILC2s exhibit the expression of GATA-binding protein 3 (GATA3) and are directly activated by cytokines originating from epithelial cells, like IL-25 and IL-33 [177]
Combining a GLP-1 agonist and a DPP-4 inhibitor for type 2 diabetes
Provider monitoring
HbA1C reductions ranged from 1.2% to 1.8% depending on dose and baseline glycemia
Genetics and receptor sensitivity Individual variation in GLP-1 receptor expression, density, and sensitivity creates a genetic component to treatment response
Similar trends were observed for systolic blood pressure, although the authors note that these analyses were exploratory and based on limited, inconsistently reported data
